Post-progression outcomes of NSCLC patients with PD-L1 expression > 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

被引：22

作者：

Cortellini, Alessio ^{[1
,2
]}

Cannita, Katia ^{[3
]}

Tiseo, Marcello ^{[4
,5
]}

Cortinovis, Diego L. ^{[6
]}

Aerts, Joachim G. J., V ^{[7
]}

Baldessari, Cinzia ^{[8
]}

Giusti, Raffaele ^{[9
]}

Ferrara, Miriam G. ^{[10
,11
]}

D'Argento, Ettore ^{[10
]}

Grossi, Francesco ^{[12
]}

Guida, Annalisa ^{[13
]}

Berardi, Rossana ^{[14
]}

Morabito, Alessandro ^{[15
]}

Genova, Carlo ^{[16
]}

Antonuzzo, Lorenzo ^{[17
]}

Mazzoni, Francesca ^{[17
]}

De Toma, Alessandro ^{[18
]}

Signorelli, Diego ^{[18
,19
]}

Gelibter, Alain ^{[20
]}

Targato, Giada ^{[21
]}

Rastelli, Francesca ^{[22
]}

Chiari, Rita ^{[23
]}

Rocco, Danilo ^{[24
]}

Gori, Stefania ^{[25
]}

De Tursi, Michele ^{[26
]}

Mansueto, Giovanni ^{[27
]}

Zoratto, Federica ^{[28
]}

Filetti, Marco ^{[9
]}

Bracarda, Sergio ^{[29
]}

Citarella, Fabrizio ^{[30
]}

Russano, Marco ^{[30
]}

Cantini, Luca ^{[7
,14
]}

Nigro, Olga ^{[31
]}

Buti, Sebastiano ^{[5
]}

Minuti, Gabriele ^{[32
]}

Landi, Lorenza ^{[32
]}

Ricciardi, Serena ^{[33
]}

Migliorino, Maria R. ^{[33
]}

Natalizio, Salvatore ^{[34
]}

Simona, Carnio ^{[35
]}

De Filippis, Marco ^{[35
]}

Metro, Giulio ^{[36
]}

Adamo, Vincenzo ^{[37
]}

Russo, Alessandro ^{[37
]}

Spinelli, Gian P. ^{[38
]}

Di Maio, Massimo ^{[39
,40
]}

Banna, Giuseppe L. ^{[41
]}

Friedlaender, Alex ^{[42
]}

Addeo, Alfredo ^{[42
]}

Pinato, David J. ^{[2
,43
]}

机构：

[1] Univ LAquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy

[2] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Div Canc, London, England

[3] St Salvatore Hosp, Med Oncol, Laquila, Italy

[4] Univ Parma, Dept Med & Surg, Parma, Italy

[5] Univ Hosp Parma, Med Oncol Unit, Parma, Italy

[6] Osped San Gerardo, Med Oncol, Monza, Italy

[7] Erasmus MC, Dept Pulm Dis, Rotterdam, Netherlands

[8] AOU Policlin Modena, Dipartimeto Oncol Ematol, Modena, Italy

[9] St Andrea Hosp, Med Oncolgy, Rome, Italy

[10] Fdn Policlin Univ Gemelli, Comprehens Canc Ctr, IRCCS, Rome, Italy

[11] Univ Cattolica Sacro Cuore, Dept Translat Med & Surg, Romae, Lazio, Italy

[12] Fdn IRCCS CaGranda Osped Maggiore Policlin, Med Oncol Unit, Milan, Italy

[13] Azienda Osped Santa Maria, Dept Oncol, Terni, Italy

[14] Univ Politecn Marche, Osped Riuniti Ancona, Oncol Clin, Ancona, Italy

[15] Ist Nazl Tumori, IRCCS, Thorac Med Oncol, Fdn G Pascale, Naples, Italy

[16] Osped Policlin San Martino, Lung Canc Unit, IRCCS, Genoa, Italy

[17] Careggi Univ Hosp, Dept Oncol, Florence, Italy

[18] Ist Nazl Tumori, Dept Med Oncol, Fdn IRCCS, Milan, Italy

[19] Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Milan, Italy

[20] Sapienza Univ Rome, Policlin Umberto I, Med Oncol B, Rome, Italy

[21] Univ Hosp Santa Maria Misericordia, Dept Oncol, Udine, Italy

[22] Med Oncol, Fermo Area Vasta 4, Fermo, Italy

[23] Osped Riuniti Padova Sud Madre Teresa Calcutta, Med Oncol, Monselice, Italy

[24] Monaldi Hosp, Pneumo Oncol Unit, Naples, Italy

[25] Osped Sacro Cuore Don Calabria, IRCCS, Oncol Unit, Negrar, VR, Italy

[26] Oral & Biotechnol Sci Univ G DAnnunzio, Dept Med, Chieti, Italy

[27] Spaziani Hosp, Med Oncol, Frosinone, Italy

[28] Santa Maria Goretti Hosp, Med Oncol, Latina, Italy

[29] Azienda Osped Santa Maria Terni, Struttura Complessa Oncol Med & Traslaz, Terni, Italy

[30] Campus Biomed Univ, Med Oncol, Rome, Italy

[31] ASST Sette Laghi, Med Oncol, Varese, Italy

[32] AUSL Romagna, Dept Oncol & Hematol, Ravenna, Italy

[33] St Camillo Forlanini Hosp, Pneumo Oncol Unit, Rome, Italy

[34] Univ Modena & Raggio Emilia, Dipartimento Oncol Ematol, Modena, Italy

[35] Univ Turin, San Luigi Hosp, Dept Oncol, Orbassano, TO, Italy

[36] Azienda Osped Perugia, Dept Med Oncol, Santa Maria Misericordia Hosp, Perugia, Italy

[37] Univ Messina, AO Papardo & Dept Human Pathol, Med Oncol, Messina, Italy

[38] Univ Rome Sapienza, UOC Terr Oncol Aprilia, AUSL Latina, Aprilia, Italy

[39] Univ Turin, Dept Oncol, Turin, Italy

[40] AO Ordine Mauriziano, Med Oncol, Turin, Italy

[41] Portsmouth Hosp Univ NHS Trust, Portsmouth, Hants, England

[42] Univ Hosp Geneva, Oncol Dept, Geneva, Switzerland

[43] Univ Piemonte Orientale, Dept Translat Med, Novara, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2021年 / 148卷

关键词：

Non-small cell lung cancer; Immunotherapy; PD-L1; Pembrolizumab; Performance status; Post-progression; Radiotherapy; Radiation therapy; CELL LUNG-CANCER; IMMUNE-CHECKPOINT INHIBITORS; SALVAGE CHEMOTHERAPY; RESPONSE RATES; IMMUNOTHERAPY; RADIOTHERAPY; ASSOCIATION; ASSAYS;

D O I：

10.1016/j.ejca.2021.02.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Treatment sequencing with first-line immunotherapy, followed by second-line chemotherapy, is still a viable option for NSCLC patients with PD-L1 expression >50%. Methods: We evaluated post-progression treatment pathways in a large real-world cohort of metastatic NSCLC patients with PD-L1 expression > 50% treated with first-line pembrolizumab monotherapy. Results: Overall, 974 patients were included. With a median follow-up of 22.7 months (95%CI: 21.6-38.2), the median overall survival (OS) of the entire population was 15.8 months (95% CI: 13.5-17.5; 548 events). At the data cutoff, among the 678 patients who experienced disease progression, 379 (55.9%) had not received any further treatment, and 359 patients (52.9%) had died. Patients who did not receive post-progression therapies were older (p = 0.0011), with a worse ECOG-PS (p < 0.0001) and were on corticosteroids prior to pembrolizumab (p = 0.0024). At disease progression, 198 patients (29.2%) received a switched approach and 101 (14.9%) received pembrolizumab ByPD either alone (64 [9.4%]) or in combination with local ablative treatments (37 [5.5%]) (LATs). After a random-case control matching according to ECOG-PS, CNS metastases, bone metastases, and (previous) best response to pembrolizumab, patients receiving pembrolizumab ByPD plus LATs were confirmed to have a significantly longer post-progression OS compared to patients receiving pembrolizumab ByPD alone 13.9 months versus 7.8 months (p = 0.0179) 241 patients (35.5%) among the 678 who had experienced PD, received a second-line systemic treatment (regardless of previous treatment beyond PD). As compared to first-line treatment commencement, patients' features at the moment of second-line initiation showed a significantly higher proportion of patients aged under 70 years (p = 0.0244), with a poorer ECOG-PS (p < 0.0001) and having CNS (p = 0.0001), bone (p = 0.0266) and liver metastases (p = 0.0148). Conclusions: In the real-world scenario NSCLC patients with PD-L1 expression >50% treated with first-line single-agent pembrolizumab achieve worse outcomes as compared to the Keynote-024 trial. Poor post-progression outcomes are major determinants of the global results that should be considered when counselling patients for first-line treatment choices. (c) 2021 Elsevier Ltd. All rights reserved.

引用

页码：24 / 35

页数：12

共 50 条

[31] Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
Pons-Tostivint, E.
Hulo, P.
Guardiolle, V.
Bodot, L.
Rabeau, A.
Porte, M.
Hiret, S.
Demontrond, P.
Curcio, H.
Boudoussier, A.
Veillon, R.
Mayenga, M.
Dumenil, C.
Chatellier, T.
Gourraud, P. A.
Mazieres, J.
Bennouna, J.
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (06) : 1881 - 1890
[32] Real World Data of First-Line Treatment With Pembrolizumab for Highly PD-L1-Expressing NSCLC
Kobayashi, M.
Mizugaki, H.
Ikezawa, Y.
Morita, R.
Tateishi, K.
Yokoo, K.
Sumi, T.
Kikuchi, H.
Nagano, Y.
Nakamura, A.
Aso, M.
Kimura, N.
Yoshiike, F.
Furuta, M.
Tanaka, H.
Sekikawa, M.
Hachiya, T.
Fujita, Y.
Oizumi, S.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1017 - S1017
[33] Real-world time on treatment (rwToT) with first-line pembrolizumab monotherapy in PD-L1 TPS ≥50% advanced NSCLC: 3-year follow-up data
Velcheti, V.
Hu, X.
Li, Y.
Burke, T.
Piperdi, B.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S755 - S755
[34] Phase III Trial of Pembrolizumab-Chemotherapy Versus Pembrolizumab in First-Line of Advanced NSCLC with PD-L1 ≥50%: PERSEE
Descourt, R.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1011 - S1011
[35] A REAL-WORLD ANALYSIS OF TREATMENT PATTERNS FOR FIRST-LINE IMMUNOTHERAPIES AMONG DANISH PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) AND PD-L1 EXPRESSION $50%
Clugston, D. M.
Beck, C.
Bjerregaard, B. K.
Kristensen, E. S.
VALUE IN HEALTH, 2023, 26 (12) : S514 - S514
[36] Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line Osimertinib
Gibson, Amanda Jane Williams
Dean, Michelle Liane
Litt, Ishjot
Box, Adrian
Cheung, Winson Y.
Navani, Vishal
CURRENT ONCOLOGY, 2024, 31 (05) : 2427 - 2440
[37] Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1 ≥ 50 % progressing on first-line pembrolizumab
Stares, Mark
Doyle, Emma
Chapple, Sally
Raynes, George
MacDonald, James
Barrie, Colin
Laird, Barry
MacKean, Melanie
Philips, Iain
LUNG CANCER, 2024, 189
[38] Baseline Derived Neutrophil-to-Lymphocyte Ratio (dNLR) and Clinical Outcomes to First-Line Pembrolizumab in NSCLC with High PD-L1 (≥50%)
Alessi, J. V.
Ricciuti, B.
Alden, S.
Awad, M.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S338 - S339
[39] Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis
Ikezawa, Yasuyuki
Morita, Ryo
Mizugaki, Hidenori
Tateishi, Kazunari
Yokoo, Keiki
Sumi, Toshiyuki
Kikuchi, Hajime
Kitamura, Yasuo
Nakamura, Atsushi
Kobayashi, Maki
Aso, Mari
Kimura, Nozomu
Yoshiike, Fumiaki
Megumi, Furuta
Tanaka, Hisashi
Sekikawa, Motoki
Hachiya, Tsutomu
Nakamura, Keiichi
Hommura, Fumihiro
Sukoh, Noriaki
Ito, Kenichiro
Kikuchi, Takashi
Agatsuma, Toshihiko
Yokouchi, Hiroshi
CANCER MEDICINE, 2024, 13 (14):
[40] Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non-Small-Cell Lung Cancer and High PD-L1 Tumor Expression
Tambo, Yuichi
Sone, Takashi
Shibata, Kazuhiko
Nishi, Kouichi
Shirasaki, Hiroki
Yoneda, Taro
Araya, Tomoyuki
Kase, Kazumasa
Nishikawa, Shingo
Kimura, Hideharu
Kasahara, Kazuo
CLINICAL LUNG CANCER, 2020, 21 (05) : E366 - E379

← 1 2 3 4 5 →

Post-progression outcomes of NSCLC patients with PD-L1 expression &gt; 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

Post-progression outcomes of NSCLC patients with PD-L1 expression > 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study